JTI Reports 10.7% Net Income Growth in Q2 2022

Jul.30.2022
JTI Reports 10.7% Net Income Growth in Q2 2022
JTI Group reports a strong performance with net income of 1.27 trillion yen ($95 billion) in Q2 2022.

The JTI Group has reported a net income of JPY 1.27 trillion (USD 9.5 billion) for the second quarter of 2022, reflecting a year-on-year growth of 10.7% compared to 2021. When calculated at a fixed exchange rate, the income growth reached 3.7%, which totaled JPY 1.14 trillion. The adjusted operating profit increased by 8% at a fixed currency rate, reaching JPY 338.77 billion. The profit also increased by 17.3% to JPY 264.1 billion.


There is no context or information provided to translate into standard journalistic English. Please provide more details or a sentence for context.


Masamichi Terabatake, President and CEO of JTI Group, announced that the company's performance in the first half of the year was strong, largely driven by advantageous product pricing. He also expressed encouragement with the performance of Ploom X and stated that the company will take advantage of Japan's expertise to guide the international release of the product in the second half of this year.


As a result of favorable fluctuations in the Chinese yuan against the Japanese yen, we have revised upwards our adjusted operating profit and profit forecasts for full-year 2022. However, taking into account the higher input costs that are affecting our supply chain operations, the constant currency-adjusted operating profit is down. The guidance for full-year dividend per share remains unchanged at 150 yen per share. The interim dividend is 75 yen per share.


Regarding Russia, despite continuing to manufacture and distribute our products in compliance with national and international sanctions, the operating environment is becoming increasingly complex. In this context, the JTI group continues to evaluate various options for its Russian business, including the possibility of transferring ownership, and will make necessary decisions in accordance with the group's management principles to address the constantly changing situation.


Please provide the text that needs to be translated.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
Reuters: Big Tobacco Emerges as Winner After FDA Regulatory Shift
According to Reuters, major tobacco companies may emerge as key beneficiaries after the U.S. FDA loosened regulations on vaping and nicotine pouch products, a shift that has sparked debate over public health risks.
Industry Insight
May.26
Product | Vaporless Mode + Transparent Display Screen: Kanger Launches Subox Mix 50K in the U.S.
Product | Vaporless Mode + Transparent Display Screen: Kanger Launches Subox Mix 50K in the U.S.
E-cigarette brand Kanger has recently launched its new e-cigarette, the Subox Mix 50K, across multiple online channels in the United States. The product features a “vaporless mode” and a transparent digital display design, supporting switching between approximately 25K vapor puffs and 25K vaporless puffs, for a total of 50,000 puffs, while displaying battery level and mode status in the transparent pod section.
Apr.13 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Special Report| War continues to shape the Ukrainian tobacco market
Special Report| War continues to shape the Ukrainian tobacco market
Four years into the war, Ukraine’s tobacco market is being reshaped by stress-driven consumption, tax pressure, youth e-cigarette use and a growing illicit segment. Surveys point to rising tobacco and nicotine product use, while higher excise duties and shadow trade are adding new complexity to the market.
Apr.17
Innovation, Insights and Networking: NUBIZ Brings the Global NGP Industry Together in Dortmund
Innovation, Insights and Networking: NUBIZ Brings the Global NGP Industry Together in Dortmund
The market for next-generation products is expanding rapidly, with vapes, e-cigarettes, pouches, snus and heat-not-burn products among the industry’s most innovative segments. As part of InterTabac, NUBIZ provides a central platform for reduced-risk tobacco and nicotine products, bringing together global leaders and newcomers from 15 to 17 September. The show combines market insights, product comparisons, networking, a high-level conference programme and exclusive side events.
Jun.03